Search

Displaying results 4291 - 4300 of 6835 in total
  1. Drug

    ARX201

    go.drugbank.com/drugs/DB05082
    Investigational

    (PEG) attachment to human growth hormone, by biosynthetic incorporation of a chemically unique amino acid (ahGH). … ARX201 (PEG-ahGH) is a recombinant form of human growth hormone that has been modified using Ambrx’s patented ReCODE™ technology to achieve precise spatial positioning of the site of polyethylene glycol

  2. Drug

    Unexpanded umbilical cord-derived allogeneic CD34- hematopoietic stem cells

    go.drugbank.com/drugs/DB28348
    Approved

    Unexpanded umbilical cord-derived allogeneic CD34- hematopoietic stem cells are one component of Zemcelpro, a cryopreserved allogeneic hematopoietic stem and progenitor cell therapy. Zemcelpro also contains dorocubicel, a preparation CD3...

  3. Drug

    Aprepitant

    go.drugbank.com/drugs/DB00673
    ApprovedInvestigational

    Aprepitant has little or no affinity for serotonin (5-HT3), dopamine, and corticosteroid receptors, the targets of existing therapies for chemotherapy-induced nausea and vomiting (CI NV).

  4. Drug

    Asimadoline

    go.drugbank.com/drugs/DB05104
    Investigational

    Asimadoline is a proprietary small molecule therapeutic, originally discovered by Merck KGaA of Darmstadt, Germany. Asimadoline was originally developed to treat peripheral pain such as arthritis.

  5. Drug

    Delorazepam

    go.drugbank.com/drugs/DB01511
    IllicitInvestigational

    It is a long acting benzodiazepine which makes it superior in this sense to lorazepam which is short acting. Lorazepam is also a major active metabolite of delorazepam. … In addition to be long acting, delorazepam is relatively potent, with 1 mg of delorazepam being the equivalent of 10 mg diazepam. It has been approved for marketing in Italy.

  6. Drug

    Lumiracoxib

    go.drugbank.com/drugs/DB01283
    ApprovedWithdrawn

    On August 11, 2007, Australia's Therapeutic Goods Administration (TGA, the Australian equivalent of the FDA) cancelled the registration of lumiracoxib in Australia due to concerns that it may cause liver

  7. Drug

    Medrysone

    go.drugbank.com/drugs/DB00253
    Approved

    Medrysone is a corticosteroid used in ophthalmology.

  8. Drug

    Albinterferon Alfa-2B

    go.drugbank.com/drugs/DB05396
    Investigational

    Human Genome Sciences modified interferon alpha to improve its pharmacological properties by using the company's proprietary albumin fusion technology. … The drug was under investigation as an alternative to pegylated IFN-α-2a for the treatment of hepatitis C.

  9. Drug

    Soy isoflavones

    go.drugbank.com/drugs/DB14101
    Approved

    Mixtures: Cheon Shim Bo Yun
  10. Drug

    Vicriviroc

    go.drugbank.com/drugs/DB06652
    Investigational

    This drug was developed by Schering-Plough.